Xenetic Biosciences- Warrants (19/07/2024) Profit Margin

Xenetic Biosciences- Warrants (19/07/2024)'s profit margin stands at -75.91% as of June 2026. That compares with -126.03% in the prior-year period — up 39.8% year over year. That is below the Healthcare sector average of 9.48%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Xenetic Biosciences- Warrants (19/07/2024) reported -75.91% in profit margin versus -126.03% a year earlier — a 39.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Xenetic Biosciences- Warrants (19/07/2024) sits lower the Healthcare benchmark (9.48%) with a profit margin of -75.91%. That is roughly 900.6% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -75.91% for Xenetic Biosciences- Warrants (19/07/2024) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Xenetic Biosciences- Warrants (19/07/2024)'s profit margin evolved across reporting periods, while the comparison chart places XBIOW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.